Latest NewsBiocon receives CRL for anti cancer drug, from USFDAadminOctober 10, 2017 by adminOctober 10, 20170979 As per Biocon, the US health regulator has issued complete response letter (CRL) for proposed biosimilar Pegfilgrastim, which is to be used in treatment for...